Aligos Therapeutics
South San Francisco, US · Founded 2018 · 3 known investors
Find your way into Aligos Therapeutics
765 people in our graph share verified history with the Aligos Therapeutics team — schools, employers, funds. One of them is your warm intro.
Lars Pedersenunlockedknows Hardean Achneck · together at Yale School of Medicine (overlapped)
×5knows the team · via Harvard Business School
knows the team · via F. Hoffmann-La Roche
knows the team · via Roche Palo Alto
knows the team · via Nova Southeastern University
×2knows the team · via Pliant Therapeutics
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.
Founders & leadership
Aligos Therapeutics was founded in 2018 by Leonid Beigelman and Lawrence M. Blatt.
LB
Leonid BeigelmaninCo-founder · President2018–2023
LM
Lawrence M. BlattinChairman, President & CEO (Co-founder)
HA
Hardean AchneckinChief Medical Officer2024–2026Hardean Achneck is a physician–scientist and dual US/EU-licensed biotech executive who served as Executive Vice President and Chief Medical Officer at Aligos Therapeutics. He previously held faculty positions as Assistant Professor of Surgery and Pathology at Duke University Medical Center and as Assistant Professor of Cardiovascular & Metabolic Disorders at Duke-National University of Singapore, and has led clinical development programs across liver diseases, infectious diseases, and rare diseases using siRNA, small-molecule, and antibody platforms.
BD
Brian DowdinExecutive Vice President2019–2020Brian Dowd began his accounting career at Deloitte in Los Angeles before spending three decades in financial leadership roles at technology and life sciences companies, with experience in IPO preparation, private equity transactions, and financial infrastructure for clinical and preclinical research organizations.
LQ
Lucinda QuaninCo-Founder & Advisor2024–2025
JS
Julian SymonsinExecutive Vice President, Chief Scientific OfficerJulian Symons holds a D.Phil. from the University of York and spent 13 years conducting academic research in immunology and virology at universities in Edinburgh, Sheffield, and Oxford before joining Roche in 1999, where he contributed to antiviral programs including the development of sofosbuvir and danoprevir for hepatitis C. He subsequently led virology activities at Alios Biopharma (acquired by Janssen/J&J in 2014) and served as Global R&D Leader for Respiratory Infections at Janssen before becoming Chief Scientific Officer of Aligos Therapeutics.
LA
Lesley Ann CalhouninExecutive Vice President, Chief Operating Officer & Chief Financial Officer
SM
Sushmita M. ChandainExecutive Vice President, Chief Development OfficerSushmita M. Chanda is Executive Vice President and Chief Development Officer of Aligos Therapeutics, a clinical-stage biotechnology company developing therapeutics for liver and viral diseases. She brings over 20 years of pharmaceutical industry experience in drug discovery, development, and safety assessment.
JH
Jim HassardinEVP, Chief Commercial OfficerJim Hassard has held sales, marketing, and commercial leadership roles across North America, Europe, and emerging markets over a 30+ year career. He has managed P&L responsibility for pharmaceutical brands from launch through maturity and led commercial teams across multiple geographies including Canada, Portugal, Switzerland, and the United States.
DB
David B. SmithExecutive Vice President, Head of Chemical Operations
PM
Peter MoldtNamed on SEC filing
MY
Michael YiNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$282.2M disclosed across 3 rounds · 2019–2025
▶$105MraisedFeb 2025 · 12 investors · BiotechnologyRule 506(b)
▶$105MraisedFeb 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bridget MartellDirector
- Julian SymonsExecutive Officer
- Margarita ChavezDirector
- K. Peter HirthDirector
- Heather PrestonDirector
- Lesley Ann CalhounExecutive Officer
- Lawrence M. BlattExecutive Officer, Director
- James ScopaDirector
- Hardean AchneckExecutive Officer
- Carole NuechterleinDirector
- Offering amount
- $105M
- Amount sold
- $105M
- Sales commissions
- $2.7M
- Placement agents
- Piper Sandler & Co., Jefferies LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$92.2MraisedNov 2023 · 11 investors · BiotechnologyRule 506(b)
▶$92.2MraisedNov 2023 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lesley Ann CalhounExecutive Officer
- Bridget MartellDirector
- Jack NielsenDirector
- Leonid BeigelmanExecutive Officer, Director
- Lucinda QuanExecutive Officer
- Carole NuechterleinDirector
- Julian SymonsExecutive Officer
- Lawrence BlattExecutive Officer, Director
- Matthew McClureExecutive Officer
- James ScopaDirector
- Peter HirthDirector
- Offering amount
- $92.2M
- Amount sold
- $92.2M
- Sales commissions
- $5.5M
- Placement agents
- PIPER SANDLER & CO.
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedJan 2020 · 38 investors · BiotechnologyRule 506(b)
▶$85MraisedJan 2020 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter HirthDirector
- Carole NeuchterleinDirector
- Jack NielsenDirector
- Peter MoldtDirector
- Sushmita ChandaExecutive Officer
- Julian SymonsExecutive Officer
- Kathleen GlaubDirector
- Brian DowdExecutive Officer
- Lucinda QuanExecutive Officer
- Leonid BeigelmanExecutive Officer, Director
- Lawrence BlattExecutive Officer, Director
- Michael YiDirector
- Tom WoiwodeDirector
- John FryExecutive Officer
- Offering amount
- $125M
- Amount sold
- $85M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Aligos Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlap
Apogee Therapeutics20 shared keywordsApogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
Robinhood19 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Aligos Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash — TradingView Newstradingview.com · Aug 2026Frequently asked questions
- What does Aligos Therapeutics do?
- Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.
- Who founded Aligos Therapeutics?
- Aligos Therapeutics was founded by Leonid Beigelman, Lawrence M. Blatt in 2018.
- Who are Aligos Therapeutics's investors?
- Aligos Therapeutics's investors include Roche Venture Fund, MPM BioVentures 2014, Vivo Capital.
- How much funding has Aligos Therapeutics raised?
- Aligos Therapeutics has disclosed $282.2M raised across 3 rounds.
- Where is Aligos Therapeutics headquartered?
- Aligos Therapeutics is headquartered in South San Francisco, US.